

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

LIGAND PHARMACEUTICALS INC

Form SC 13G/A

February 12, 2004

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)

(Amendment No.1)

Ligand Pharmaceuticals Incorporated

(Name of Issuer)

Common Stock

(Title of Class of Securities)

53220K207

(CUSIP Number)

December 31, 2003

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

(1) The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).

CUSIP No. 53220K207

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield Capital, L.P.
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ☐
(b) ☒
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
- NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5. SOLE VOTING POWER

0
6. SHARED VOTING POWER

2,155,905
7. SOLE DISPOSITIVE POWER

0
8. SHARED DISPOSITIVE POWER

2,155,905
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,155,905
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

[-]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

2.95%
12. TYPE OF REPORTING PERSON*

PN

CUSIP No. 533220K207

1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield Partners, L.P.

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ☐
(b) ☒

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

New York

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER

0

6. SHARED VOTING POWER

2,155,905

7. SOLE DISPOSITIVE POWER

0

8. SHARED DISPOSITIVE POWER

2,155,905

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,155,905

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

☐

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

2.95%

12. TYPE OF REPORTING PERSON*

PN

CUSIP No. 53220K207

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield Management Company, L.P.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ☐
(b) ☒

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

New York

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER

0

6. SHARED VOTING POWER

2,071,360

7. SOLE DISPOSITIVE POWER

0

8. SHARED DISPOSITIVE POWER

2,071,360

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,071,360

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

☐ [-]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

2.83%

12. TYPE OF REPORTING PERSON*

PN

CUSIP No. 53220K207

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Deerfield International Limited

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ☐

(b) ☒

3. SEC USE ONLY

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

4. CITIZENSHIP OR PLACE OF ORGANIZATION

British Virgin Islands

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER

0

6. SHARED VOTING POWER

2,071,360

7. SOLE DISPOSITIVE POWER

0

8. SHARED DISPOSITIVE POWER

2,071,360

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,071,360

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

☐ [-]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

2.83%

12. TYPE OF REPORTING PERSON*

CO

CUSIP No. 53220K207

1. NAME OF REPORTING PERSONS

I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Arnold H. Snider

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) ☐ [-]

(b) ☒ [X]

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

5. SOLE VOTING POWER

6. SHARED VOTING POWER

4,227,265

7. SOLE DISPOSITIVE POWER

8. SHARED DISPOSITIVE POWER

4,227,265

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,227,265

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

[-]

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

5.78%

12. TYPE OF REPORTING PERSON*

IN

CUSIP No. 53320K207

Item 1(a). Name of Issuer:

Ligand Pharmaceuticals Incorporated

Item 1(b). Address of Issuer's Principal Executive Offices:

10275 Science Center Drive
San Diego, California 92121-1117

Item 2(a). Name of Person Filing:

Arnold H. Snider, Deerfield Capital, L.P., Deerfield Management
Company, L.P., Deerfield International Limited

Item 2(b). Address of Principal Business Office, or if None, Residence:

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

Arnold H. Snider, Deerfield Capital, L.P., Deerfield Management Company, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017

Deerfield International Limited, c/o Hemisphere Management (B.V.I.) Limited, Bison Court, Columbus Centre, P.O. Box 3460, Road Town, Tortola, British Virgin Islands

Item 2(c). Citizenship:

Mr. Snider - United States citizen

Deerfield Capital, L.P. and Deerfield Partners,
L.P. - Delaware limited partnerships

Deerfield Management Company, L.P. - New York limited
partnership

Deerfield International Limited - British Virgin
Islands corporation

Item 2(d). Title of Class of Securities:

Common Stock

Item 2(e). CUSIP Number:

53320K207

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

- (a) ☐ Broker or dealer registered under Section 15 of the Exchange Act.
- (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
- (c) ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act.
- (d) ☐ Investment company registered under Section 8 of the Investment Company Act.
- (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
- (g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

(i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

(j) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

Deerfield Capital, L.P. and Deerfield Partners, L.P. - 2,155,905 shares; Deerfield Management Company, L.P. and Deerfield International Limited - 2,071,360 shares; Arnold H. Snider - 4,227,265 shares.

(b) Percent of class:

Deerfield Capital, L.P. and Deerfield Partners, L.P. - 2.95%; Deerfield Management Company, L.P. and Deerfield International Limited - 2.83%; Arnold H. Snider - 5.78%

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote 0
-----,

(ii) Shared power to vote or to direct the vote Deerfield Capital,
L.P. and Deerfield
Partners, L.P. -
2,155,905;
Deerfield
Management Company,
L.P. and Deerfield
International
Limited -
2,071,360;
Arnold H. Snider -
4,227,265
-----,

(iii) Sole power to dispose or to direct the disposition of 0
-----,

(iv) Shared power to dispose or to direct the disposition of
Deerfield Capital,
L.P. and Deerfield
Partners, L.P. -
2,155,905;
Deerfield
Management Company,
L.P. and Deerfield
International
Limited -
2,071,360; Arnold

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

H. Snider -
4,227,265

-----.

The Reporting Persons specifically disclaim beneficial ownership in the securities reported herein except to the extent of their pecuniary interest therein.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following [].

N/A

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

N/A

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item 10. Certifications.

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect."

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DEERFIELD CAPITAL, L.P.

By: Snider Capital Corporation ,
General Partner

By: /s/ Arnold H. Snider

Arnold H. Snider, President

DEERFIELD PARTNERS, L.P.

By: Deerfield Capital, L.P.

By: Snider Capital Corporation,
General Partner

By: /s/ Arnold H. Snider

Arnold H. Snider, President

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Snider Management Corporation,
General Partner

By: /s/ Arnold H. Snider

Arnold H. Snider, President

DEERFIELD INTERNATIONAL LIMITED

By: Deerfield Management Company, L.P.

By: Snider Management Corporation,
General Partner

By: /s/ Arnold H. Snider

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

Arnold H. Snider, President

ARNOLD H. SNIDER

/s/ Arnold H. Snider

Date: February 11, 2004

Exhibit A

Agreement

The undersigned agree that this Schedule 13G dated February 11, 2004 relating to the Common Stock of Ligand Pharmaceuticals Incorporated shall be filed on behalf of the undersigned.

DEERFIELD CAPITAL, L.P.

By: Snider Capital Corporation,
General Partner

By: /s/ Arnold H. Snider

Arnold H. Snider, President

DEERFIELD PARTNERS, L.P.

By: Deerfield Capital, L.P.

By: Snider Capital Corporation,
General Partner

By: /s/ Arnold H. Snider

Arnold H. Snider, President

DEERFIELD MANAGEMENT COMPANY, L.P.

By: Snider Management Corporation
General Partner

By: /s/ Arnold H. Snider

Arnold H. Snider, President

DEERFIELD INTERNATIONAL LIMITED

By: Deerfield Management Company, L.P.

By: Snider Management Corporation,
General Partner

By: /s/ Arnold H. Snider

Arnold H. Snider, President

Edgar Filing: LIGAND PHARMACEUTICALS INC - Form SC 13G/A

ARNOLD H. SNIDER

/s/ Arnold H. Snider

00871.0001 #462760